Structure Therapeutics Inc.
Business
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics targeting G-protein coupled receptors (GPCRs) to treat chronic diseases with unmet medical need. The company's lead program is aleniglipron (GSBR-1290), an oral GLP-1 receptor agonist in Phase 2b clinical development for obesity; the pipeline also includes oral amylin receptor agonists (ACCG-2671, ACCG-3535), GIP and glucagon receptor modulators for potential combination therapy, and other preclinical GPCR-targeted candidates. The company operates a structure-based drug discovery platform leveraging computational chemistry capabilities through its strategic partnership with Schrödinger, targeting metabolic, cardiovascular and pulmonary disease indications globally.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Research and development | 225 | 109 | 70 | 36 | |
| General and administrative | 62 | 49 | 33 | 16 | |
| Other license income | −100 | — | — | — | |
| Gains on sale of non-financial assets | −10 | — | — | — | |
| Total operating expenses | 177 | 158 | 103 | 53 | |
| Loss from operations | −177 | −158 | −103 | −53 | |
| Interest and other income, net | 36 | 36 | 13 | 1 | |
| Loss before provision for income taxes | −141 | −122 | −89 | −51 | |
| Provision for income taxes | 515,000 | 310,000 | 236,000 | 17,000 | |
| Net loss attributable to ordinary shareholders | −141 | −123 | −90 | −51 | |
| Net loss per share, basic | −0.8 | −0.78 | −0.81 | −5.51 | |
| Net loss per share, diluted | −0.8 | −0.78 | −0.81 | −5.51 | |
| Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic | 178 | 158 | 110 | 10 | |
| Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted | 178 | 158 | 110 | 10 | |
| Unrealized gain on investments, net | 140,000 | 393,000 | 631,000 | −110,000 | |
| Total other comprehensive income | 140,000 | 393,000 | 631,000 | −110,000 | |
| Comprehensive loss | −141 | −122 | −89 | −51 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 800 | 170 | 130 | 26 | — | |
| Short-term investments | 647 | 714 | 338 | 65 | — | |
| Other receivable | 100 | — | — | — | — | |
| Prepaid expenses and other current assets | 24 | 8 | 6 | 2 | — | |
| Total current assets | 1,570 | 891 | 474 | 93 | — | |
| Property and equipment, net | 7 | 3 | 3 | 1 | — | |
| Operating right-of-use assets | 6 | 4 | 5 | 262,000 | — | |
| Other non-current assets | 717,000 | 5 | 45,000 | 3 | — | |
| Total assets | 1,584 | 903 | 482 | 98 | — | |
| Accounts payable | 14 | 8 | 5 | 6 | — | |
| Accrued expenses and other current liabilities | 47 | 26 | 19 | 7 | — | |
| Operating lease liabilities, current portion | 3 | 2 | 1 | 260,000 | — | |
| Total current liabilities | 63 | 36 | 25 | 13 | — | |
| Operating lease liabilities, net of current portion | 4 | 2 | 4 | — | — | |
| Other non-current liabilities | 647,000 | 302,000 | 298,000 | — | — | |
| Total liabilities | 68 | 38 | 29 | 13 | — | |
| Commitments and contingencies (Note 5) | — | — | — | — | — | |
| Undesignated shares - $0.0001 par value; 100,000 shares authorized as of December 31, 2025 and December 31, 2024 | — | — | — | — | — | |
| Ordinary shares - $0.0001 par value; 500,000 shares authorized as of December 31, 2025 and December 31, 2024; 212,513 and 171,860 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 21,000 | 17,000 | 14,000 | 1,000 | — | |
| Additional paid-in capital | 1,986 | 1,193 | 659 | 2 | — | |
| Accumulated other comprehensive income | 1 | 914,000 | 521,000 | −110,000 | — | |
| Accumulated deficit | −470 | −329 | −207 | −117 | — | |
| Total shareholders' equity | 1,516 | 865 | 453 | −115 | −65 | |
| Total liabilities and shareholders' equity | 1,584 | 903 | 482 | 98 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Net loss | −141 | −123 | −90 | −51 | |
| Share-based compensation expense | 29 | 19 | 8 | 3 | |
| Depreciation expense | 1 | 1 | 300,000 | 277,000 | |
| Accretion of asset retirement obligation | 345,000 | 4,000 | 21,000 | — | |
| Non-cash lease expense | 2 | 2 | 634,000 | 347,000 | |
| Accretion of net investment discounts | −16 | −18 | −6 | −905,000 | |
| Other receivable | −100 | — | — | — | |
| Prepaid expenses and other current assets | −16 | −1 | −4 | −305,000 | |
| Other non-current assets | 4 | −5 | 15,000 | −60,000 | |
| Accounts payable | 5 | 3 | −860,000 | 2 | |
| Accrued expenses and other current liabilities | 22 | 8 | 12 | 2 | |
| Operating lease liabilities | −2 | −2 | −315,000 | −361,000 | |
| Net cash used in operating activities | −222 | −117 | −79 | −46 | |
| Purchases of short-term investments | −547 | −703 | −417 | −123 | |
| Proceeds from maturities of short-term investments | 631 | 345 | 151 | 62 | |
| Purchases of property and equipment | −4 | −1 | −2 | −155,000 | |
| Proceeds from sale of non-financial asset | 10 | — | — | — | |
| Net cash provided by (used in) investing activities | 90 | −359 | −268 | −62 | |
| Proceeds from issuance of pre-funded warrants in 2025 Follow-On Offering, net of underwriting discounts and commissions | 94 | — | — | — | |
| Proceeds from issuance of ordinary shares in initial public offering, net of underwriting discounts and commissions | — | — | 172 | — | |
| Proceeds from private placement financing, gross | — | — | 300 | — | |
| Payments of offering costs | −2 | −2 | −22 | — | |
| Proceeds from issuance of ordinary shares under employee share purchase plan | 921,000 | 632,000 | — | — | |
| Proceeds from exercise of share options | 5 | 2 | 800,000 | 33,000 | |
| Payment of taxes on restricted share units withheld for taxes | −618,000 | — | — | — | |
| Net cash provided by financing activities | 763 | 515 | 452 | 29 | |
| Net change in cash and cash equivalents | 630 | 40 | 104 | −79 | |
| Offering costs included in accounts payable and accrued expenses and other current liabilities | 442,000 | 100,000 | 53,000 | — | |
| Operating lease right-of-use assets obtained in exchange for new lease liabilities | 5 | — | 6 | — | |
| Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities | 894,000 | — | 48,000 | — | |
| Conversion of redeemable convertible preferred shares into ordinary shares upon initial public offering | — | — | 200 | — | |
| Recognition of asset retirement obligation | — | — | 277,000 | — | |
| Conversion of non-voting ordinary shares into ordinary shares | — | — | 1,000 | — | |
| Exchange of ordinary shares to non-voting ordinary shares | — | — | 1,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Structure Therapeutics Inc.'s CIK number?
Structure Therapeutics Inc.'s SEC CIK number is 0001888886 (1888886). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Structure Therapeutics Inc.'s SEC filings?
All of Structure Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Structure Therapeutics Inc. last report earnings?
Structure Therapeutics Inc. (GPCR) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-057226). This is Structure Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Structure Therapeutics Inc.'s most recent earnings 8-K?
Structure Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001104659-26-057226. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Structure Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →